Good MorningEquity markets fell hard on Monday to not only confirm resistance at the S&P 500 level of 4,300 but to break through potential support at the 4,150 level as well. The move also confirms a much larger Head & Shoulders pattern that has been in play all year. This pattern has not only a long-term but a deep implication that could lead the S&P 500 down to the 2,700 level and keep it trending at low levels for an extended period of time. The major culprit for the move is slowing economic activity and the possibility of a deepening recession.
This week, the biggest risk for the market will come on Friday with the release of the PCE Price Index. The index is expected to show a slowdown in the monthly advance of consumer level inflation but for core consumer inflation to remain at record levels on a YOY basis. A better-than-expected figure could send the market higher but a worse-than-expected number will most defiantly send it lower on an increased expectation for another aggressive FOMC interest rate increase. Featured: Wall Street’s quietly buying these 3 AI infrastructure plays (Ad) 
|
Basic Materials | | Global demand for copper is soaring, but does that put suppliers like Freeport-McMoRan (NYSE:FCX), Teck Resources (NYSE: TECK) and Southern Copper (NYSE: SCCO) in a position to rally?
Copper is a crucial component in several areas poised for growth: Electric vehicles, wind and solar power, and the... Read the Full Story |
|
From Our Partners | | BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid.
The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned. | | Get the name, the ticker, and exactly how to buy it |
|
Industrials | |
Industrial stocks are ideal to buy in a bull market. Companies tend to increase spending when their cost of capital is cheap. But with rising interest rates, an uncertain employment picture, and geopolitical concerns industrial stocks look less compelling.
And as an overall sector, that’s... Read the Full Story |
|
Consumer Staples | |
Besides the shared nomenclature, Beyond Meat, Inc. (NASDAQ: BYND) may have more in common with Bed Bath & Beyond than “meats” the eye.
Last week shares of the specialty retailer soared as high as $30 despite an absence of news. Traders bought more than $130 million worth of the po... Read the Full Story |
|
From Our Partners | | See the Signals Most Traders Miss
We monitor subtle shifts in order flow, volume patterns, and early trend behavior.
Stock News Trends highlights moves long before they hit mainstream screens. | | Join Free — Start Tracking Early Market Data |
|
Markets | | Oil-and-gas explorer and producer Denbury (NYSE: DEN) has been in rally mode since mid-July and is working on its second month in a row of double-digit price gains. Both earnings and rumors of a sale are driving the increases.
The stock bolted 19.87% higher in July, and has tacked on another 28.56%... Read the Full Story |
|
Finance | |
Insurance fintech platform provider Lemonade (NYSE: LMND) stock has surged off its $15.99 lows in May to double after its earnings release in August 2022. The insurtech disruptor is trying to break the conventional mold in the five trillion dollar insurance industry. It’s artificial intellig... Read the Full Story |
|
From Our Partners | | With OpenAI and Anthropic moving closer to the IPO spotlight, AI excitement could spill into several public-market sectors this summer - and most investors may chase the obvious names too late.
A free report identifies 7 stocks positioned around themes that could matter most this summer: AI infrastructure, energy demand, travel, entertainment, home improvement, and more. Built for a market where leadership may rotate quickly. | | Download 7 Best Stocks to Own in Summer 2026 for free |
|
Energy | |
The results from oil services companies like Baker Hughes (NYSE: BKR), Haliburton (NYSE: HAL), and Schlumberger (NYSE: SLB) were mixed to be sure but there is one common thread among them. The outlook for spending on oil-field services remains strong and supportive of a multi-year upcycle for the ... Read the Full Story |
|
Technology | | Integrated circuits (IC) developer Analog Devices (NYSE: ADI) stock took a rapid rug pull after revealing the softening of demand in its recent earnings report. Shares are trading down (-5.5%) for the year which is still an improvement over the Nasdaq 100 (NASDAQ: QQQ) down (-19%). The maker of inte... Read the Full Story |
|
Finance | |
It’s easy to find hot stocks in a hot market because a rising tide lifts all ships. It’s much harder to find hot stocks when the market for the S&P 500 (NYSE: ARCA) is tepid because investors and their money are more cautious. In this scenario, stocks will generally move sideways w... Read the Full Story |
|
Markets | |
As summer days go, the July 4th holiday swiftly passed a while back, but the fireworks are still popping in the U.S. equity markets.
Some of the more explosive booms have come in response to second-quarter earnings reports. From Walt Disney and PayPal to Uber and Enphase Energy, companies across ... Read the Full Story |
|
Basic Materials | | The passage of the Inflation Reduction Act (IRA) places a huge spotlight back on global decarbonization efforts promoting the use of clean and renewable energy sources. The law provides for $430 billion towards investment in clean energy technologies and the reduction of greenhouse gas emissions. Nu... Read the Full Story |
|
Tuesday's Early Bird Stock Of The Day Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts. | | View Today's Stock Pick |
|
